What is the prevalence of Multiple myeloma?

Multiple myeloma is a hematologic malignancy characterized by the clonal proliferation of plasma cells in the bone marrow, with an estimated prevalence of approximately 140,000–150,000 people living with the condition in the United States alone. While often classified as a rare disease in specific contexts, it represents about 1% of all cancers and 10% of hematologic malignancies, with an annual incidence of approximately 6 to 7 cases per 100,000 individuals worldwide.

Is Multiple myeloma considered a rare disease?

While Multiple myeloma is frequently categorized as a rare disease in clinical research due to its relatively low incidence compared to solid tumors, its prevalence is increasing due to improved survival rates from modern therapies. At DiseaseMaps.org, 217 community members currently share their experiences with Multiple myeloma, offering vital real-world data that complements clinical statistics. Accurate prevalence data can be challenging to capture, as early-stage disease—often termed Monoclonal Gammopathy of Undetermined Significance (MGUS)—may remain undiagnosed for years.

Who is most commonly affected by Multiple myeloma?

Epidemiological patterns for Multiple myeloma show significant demographic trends:

• Age of Onset: It is primarily a disease of older adults; the median age at diagnosis is approximately 69 years, with very few cases occurring in individuals under 40.


• Gender Distribution: Men are slightly more likely to be diagnosed with Multiple myeloma than women, with a ratio of approximately 1.5:1.


• Ethnic Variation: Incidence rates are notably higher in African American populations, where the risk of developing Multiple myeloma is roughly double that of Caucasian populations.

Why are prevalence statistics sometimes difficult to track?

Tracking the exact number of people living with Multiple myeloma is complicated by the transition from asymptomatic pre-malignant states (MGUS or smoldering myeloma) to active disease. Misdiagnosis is also a factor, as initial symptoms like bone pain or fatigue may be attributed to common age-related conditions, leading to delays in definitive hematological evaluation.

Next steps

• Consult a hematologist-oncologist specializing in plasma cell dyscrasias for a comprehensive diagnostic review.


• Join the Multiple myeloma community at DiseaseMaps.org to connect with others and track your patient journey.


• Stay informed on clinical trials via the NIH or International Myeloma Foundation to understand emerging therapeutic options.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of a physician regarding a medical condition.

References

• American Cancer Society (Cancer Facts & Figures)


• NIH National Cancer Institute (Surveillance, Epidemiology, and End Results Program)


• Orphanet (Rare Diseases Database)


• International Myeloma Foundation (Global Prevalence Data)